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OBJECTIVE — To clarify the association of circulating levels of leptin with risk for cardio-
vascular disease (CVD) events and new-onset diabetes in men and women.
RESEARCH DESIGN AND METHODS — We related baseline leptin levels to CVD
events (n  864) and incident diabetes (n  289) in an elderly population (n  5,672) over 3.2
years of follow-up.
RESULTS — Intreatment-,age-,andcountry-adjustedmodels,leptinwasnotassociatedwith
risk of CVD in men (hazard ratio 1.02 [95% CI 0.90–1.16] per unit log-leptin increase) or
women (1.05 [0.91–1.20]) but was associated with risk of diabetes in men (2.75 [2.14–3.52])
and women (1.54 [1.22–1.94]). After adjusting for classic risk factors and BMI, C-reactive
protein, and glucose, the diabetes association retained signiﬁcance in men (1.85 [1.30–2.63])
but not in women (0.89 [0.64–1.26]).
CONCLUSIONS — Leptin,similartoothermarkersofadiposityingeneral,ismorestrongly
related to risk of diabetes than CVD in the elderly.
Diabetes Care 32:308–310, 2009
L
eptin is a pleiotropic adipokine, and
circulating levels correlate with
markers of body fat mass (1). Obe-
sity is a known risk factor for the devel-
opment of both cardiovascular disease
(CVD) and type 2 diabetes, and leptin is a
candidate mediator of these increased
risks. Hyperleptinemia may promote ath-
erosclerosis (2), and dysregulation of lep-
tin signaling in obese individuals results
in reduced fatty acid oxidation and glu-
cose uptake (3).
There is evidence for (4–6) and
against (7–10) leptin being a prospective
risk marker for CVD, whereas there is ev-
idence that leptin predicts diabetes risk
independently of other confounders only
inmen(11–13).Weaimedtoclarifythese
risk associations by simultaneous com-
parison of end points in both sexes indi-
vidually in a single study.
RESEARCH DESIGN AND
METHODS— Methods of the PRO-
spective Study of Pravastatin in the
Elderly at Risk trial (PROSPER) as an an-
cillary risk association study have been
reported (14). Between 1997 and 1999,
5,804menandwomenaged70–82years
were recruited from Scotland, Ireland, or
the Netherlands if they had either preex-
isting vascular disease (coronary, cere-
bral, or peripheral) or increased risk of
such disease because of risk factors. The
institutional ethics review boards of all
centers approved the protocol, and all
participants gave written informed con-
sent. The primary outcome was deﬁnite
or suspect death from coronary heart dis-
ease (CHD), nonfatal myocardial infarc-
tion, or fatal or nonfatal stroke. New-
onset diabetes was classiﬁed as detailed
(14) excluding those with known (n 
606)andundiagnoseddiabetes(n134)
based on baseline glucose measurements
(95% fasting). CVD events were vali-
dated by a committee blinded to the end
points.
Fasting morning baseline leptin was
measured by an in-house radioimmuno-
assay validated thoroughly against the
commercially available Linco assay. The
intra- and interassay coefﬁcients of varia-
tion(CVs)were7%and10%,respec-
tively.Thedetectionlimitoftheassaywas
0.5 ng/ml. Samples were processed with
investigators blinded to the identity of
samples.
The distribution of leptin was posi-
tively skewed, and a logarithmic transfor-
mation was used. Relationships between
log-leptin and BMI were assessed using
Pearson’s correlation coefﬁcient. The in-
ﬂuence of leptin on the end points of in-
terest was investigated in each sex using
Cox proportional hazards models (using
sex-speciﬁc standard deviations), adjust-
ing for randomized treatment, age, coun-
try, and other risk factors (LDL and HDL
cholesterol, triglycerides, blood pressure,
smoking, BMI, antihypertensive medica-
tions, history of vascular disease, C-reac-
tive protein, and glucose) in models
described. Results are reported as hazard
ratio (95% CI) for 1-unit increases in log-
leptin and corresponding P value.
RESULTS— Plasma leptin levels were
available in 5,672 patients. During 3.2
years of follow-up, 864 had a primary
CVD end point and 289 were newly diag-
nosed with diabetes (from 4,934 partici-
pantsexcludingbaselinediabeticsubjects
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Faculty of Medicine, University of Glasgow, Scotland, U.K.; the
2Robertson Centre for Biostatis-
tics, University of Glasgow, Scotland, U.K.; the
3Department of Pharmacology and Therapeutics, Cork
University Hospital, Wilton, Cork, Ireland; the
4Department of Gerontology and Geriatrics, Leiden
University Medical Centre, Utrecht, The Netherlands; and the
5Department of Cardiology, Leiden Uni-
versity Medical Centre, Utrecht, The Netherlands.
Corresponding author: Paul Welsh, p.welsh@clinmed.gla.ac.uk.
Received 27 August 2008 and accepted 30 October 2008.
Published ahead of print at http://care.diabetesjournals.org on 10 November 2008. DOI: 10.2337/dc08-
1458.
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Epidemiology/Health Services Research
BRIEF REPORT
308 DIABETES CARE, VOLUME 32, NUMBER 2, FEBRUARY 2009and those with missing values). The base-
line characteristics of the population have
been reported (14). Leptin levels were
slightlyloweramongthoseexperiencinga
primary vascular end point (mean  SD
12.42.43ng/mlvs.13.52.43ng/ml,
P  0.0095). The strongest correlate of
leptin in this study was BMI (r  0.59,
P  0.0001).
Leptin showed no association with
CVDriskinminimallyadjustedmodelsor
in other multivariable analyses in men or
women(Table1).Thiswasalsotruewhen
examining associations separately with
CHD and stroke. The ﬁndings were sim-
ilar in those with ﬁrst-time versus sec-
ondary CVD events in either sex (data not
shown).
For diabetes, risk associations were
signiﬁcant in both men and women after
adjusting for basic confounders (model
A). Stepwise adjustment for additional
confounders (model B) and BMI (model
C) revealed that BMI mediated a signiﬁ-
cant proportion of the risk association in
women. The association of leptin with di-
abetes risk was not signiﬁcant in women
in model C but persisted in men, even
after adjusting for both BMI and glucose
(model D). Leptin had a greater associa-
tionwithdiabetesinmenthaninwomen;
the 95% CIs do not overlap in any model.
In all models, there was no signiﬁcant
interaction by treatment allocation, al-
though this variable was adjusted for in
any case.
CONCLUSIONS— Recent ﬁndings
(7,10) reported no association of leptin
with CHD risk in women. Investigators
suggested a need to conﬁrm these ﬁnd-
ings in both sexes in larger studies (10).
Our study does this in the largest study of
leptin and CVD risk associations to date.
PROSPER ﬁndings contrast with those of
the West of Scotland Coronary Preven-
tion (WOSCOP) study, although the as-
sociation reported in that study was
modest (univariable relative risk 1.25 per
SD increase) (4). We suggest that leptin is
not likely to be an important risk marker
for CVD events.
In agreement with other reports (11–
13), we report that leptin is a risk marker
of diabetes, but the association is signiﬁ-
cantlystrongerinmen.Thesexdifference
in terms of leptin’s diabetes risk associa-
tions is not well understood but, specula-
tively, may reﬂect differing distributions
of adipose tissue in men versus women.
Women have more total and subcutane-
ous fat (a major producer of leptin) and,
accordingly, higher leptin levels. Men
have a greater percentage of visceral fat
mass and are at greater risk of diabetes
than women per unit of circulating leptin
increase. Adjustment models not includ-
ing insulin resistance leave residual asso-
ciationswithriskfordiabetesinmen(13)
butnotinwomen.However,inetiological
terms, adjusting leptin’s association with
diabetes risk for insulin resistance may be
an over-adjustment.
Strengths and limitations of the study
have been considered (14). The study
stems from a statin trial (14), but we ob-
served no interaction by treatment for
leptin’s associations with end points of in-
terest, and all analyses were adjusted for
treatment allocation. The participants were
elderly, but associations with end points
were broadly similar to those observed
(separately for CVD and diabetes) in
younger populations (10,12). Thus, our re-
sults have external validity. The present
study, however, cannot establish whether
hyperleptinemia per se or leptin resistance
explains the reported association between
circulating leptin and incident diabetes.
In summary, circulating leptin levels
are unlikely to be a unifying link between
obesity, CVD, and diabetes risk. Leptin,
like other markers of adiposity (BMI and
waist circumference) in middle-aged and
elderly populations (14), is more strongly
relatedtoriskofdiabetesthanCVDinthe
elderly.
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